Low-dose decitabine priming endows CAR T cells with enhanced and persistent antitumour potential via epigenetic reprogramming.
Wang Y, Tong C, Dai H, Wu Z, Han X, Guo Y, Chen D, Wei J, Ti D, Liu Z, Mei Q, Li X, Dong L, Nie J, Zhang Y, Han W.
Wang Y, et al. Among authors: han x, han w.
Nat Commun. 2021 Jan 18;12(1):409. doi: 10.1038/s41467-020-20696-x.
Nat Commun. 2021.
PMID: 33462245
Free PMC article.